JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Genes Dev
Autors principals: Kim, Sang-Kyu, Knight, Deborah A., Jones, Lisa R., Vervoort, Stephin, Ng, Ashley P., Seymour, John F., Bradner, James E., Waibel, Michaela, Kats, Lev, Johnstone, Ricky W.
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory Press 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6049517/
https://ncbi.nlm.nih.gov/pubmed/29907650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.307504.117
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars